natgillin/translations-raw huggingface dataset:
The alkanoyl groups can be acetyl or higher, for example up to C20. 
Alkanoil grupe mogu biti acetil ili više, na primjer do C2g.
A method of transmitting a broadcasting signal, the method comprising: building a signal frame comprising one or more data slices carrying a Physical Layer Pipe, PLP, and one or more preamble symbols carrying Layer 1, L1, signaling data for the data slices, wherein the preamble symbols are divided in frequency direction into at least two L1 blocks of same bandwidth, and the signal frame comprises a layer-2 information including a network information table (NIT) having an identifier of a physical layer pipe (PLP_id) and an identifier of a C2 system (C2_system_id) corresponding to a transport stream, TS, in the signal frame; 
Postupak odašiljanja emitiranog signala, postupak obuhvaća: građenje okvira signala koji obuhvaća jedan ili više podatkovnih komada koji nose PLP, i jedan ili više pilot simbola koji nose Sloj 1, L1, signalnih podataka za podatkovne komade, gdje su pilot simboli podijeljeni prema smjeru frekvencije u barem dva LI bloka iste širine pojasa, i okvir signala obuhvaća sloj-2 informaciju uključujući tablicu s mrežnim podacima (NIT) 1 ima identifikator PLP-a (PLP_id) 1 identifikator C2 sustava (C2_system_id) koji odgovara prijenosnom toku, TS, u okviru signala; modulaciju okvira signala pomoću ortogonalne modulacijske tehnike u frekvencijskoj domeni (OFDM); 1 odašiljanje moduliranog okvira signala, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a 1 identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava.
In case the sealing member 8 is a separate piece attached to the capsule 1, it can be mounted to the capsule as one integral piece. 
U slučaju da je element za nepropusno zatvaranje 8 odvojeni komad koji je pričvršćen na čahuru 1, on može biti montiran na čahuru kao integralni komad.
The composition of claim 9 wherein the composition comprises a concentrated formulation selected from the group consisting of a capsule suspension, an oil dispersion, an oil flowable, a suspension concentrate, a suspoemulsion and mixtures thereof. 
Pripravak prema zahtjevu 9 naznačen time da pripravak sadrži koncentriranu formulaciju odabranu iz skupine koja sadrži suspenziju u kapsuli, uljnu disperziju, uljni tekući suspenzijski koncentrat, suspoemulziju i njihove smjese.
The reaction mixture is stirred at room temperature for 2 hours and then filtered and concentrated in vacuo to yield the titled compound as an orange oil which is used crude in the next step. 
Reakcijsku smjesu se miješa 2 sata pri sobnoj temperaturi i zatim se profiltrira i koncentrira u vakuumu, čime se dobije naslovni spoj kao narančasto ulje koje se koristi sirovo u slijedećem stupnju.
In some embodiments, the retinyl ester is a 9-cis-retinyl ester of a C3 to C22 carboxylate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester Ci-C19 monokarboksilata.
The plasma exposure to gemcitabine was increased in CD-1 mice when the compound of Example 1 was administered, compared to direct oral administration of gemcitabine hydrochloride. 
Izloženost plazme gemcitabinu povećana je kod CD-1 miševa kada je primijenjen spoj iz Primjera 1, u usporedbi s izravnom oralnom primjenom gemcitabin-hidroklorida.
Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims. A pharmaceutical composition comprising C1 esterase inhibitor, sodium citrate, and having a pH ranging from 6.5-8.0, wherein the C1 esterase inhibitor has a concentration of about 500 U/mL, and wherein the C1 esterase inhibitor comprises the amino acid sequence of residues 23 to 500 of SEQ ID NO: 1. 
Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da je najmanje jedan inhibitor C1 esteraze izoliran ili pročišćen iz ljudske plazme ili je dobiven pomoću tehnika rekombinacije, i/ili pri čemu inhibitor C1 esteraze ima sekvencu amino kiselina 90%, 95%, 98%, 99% ili 100% identičnu s ljudskom sekvencom amino kiselina inhibitora C1 esteraze na slici 1.
A compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof; 
HR P20171915 T1 PATENTNI ZAHTJEVI 1. Spoj predstavljen sljedećom strukturnom formulom:
Pharmaceutical composition according to one of the aspects 1-3 comprising an effective dose of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9 (human proprotein convertase subtilisin/kexin type 9), wherein the dose is sufficient for sustained reduction of low-density lipoprotein (LDL-C) levels over a period of at least 14, at least 15, at least 16, at least 17, at least18, at least 19, at least 20, at least 21, at least 22, at least 23 or at least 28 days after administration, together with a pharmaceutically acceptable excipient or carrier. 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 3, naznačen time da sadrži učinkovitu dozu protutijela ili njegovog fragmenta koji veže antigen, pri čemu je doza dovoljna za održivo smanjenje razina lipoproteina niske gustoće (LDL-C) tijekom perioda od barem 14, barem 15, barem 16, barem 17, barem 18, barem 19, barem 20, barem 21, barem 22, barem 23 ili barem 28 dana nakon primjene.
Preferably, spinal neurodegenerative disorders are amyotrophic lateral sclerosis, multiple sclerosis, spinal muscular atrophy and neurodegeneration due to spinal cord injury. Advantageously, mood disorders are bipolar disorders and depressive disorders. 
1H-indazol-3-karboksamid za uporabu prema zahtjevu 14, naznačen time, da su navedeni spinalni neurođegenerativni poremećaji odabrani iz skupine koju čine amiotrofna lateralna skleroza, multipla skleroza, spinalna muskularna atrofija i neurođegeneracija zbog ozljede kralježnične moždine.
Use of nanoparticles or nanoparticles' aggregates for the preparation of a pharmaceutical composition for use in a method of altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Uporaba nanočestica ili agregata nanočestica za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada se te stanice izlože ionizirajućim zračenjima, pri čemu se svaka nanočestica ili agregat nanočestica sastoji od metalnog oksida odabranog iz skupine koju čine CeO2, Tm2O3, HfO2, WO3 i PdO, gdje je gustoća te nanočestice ili agregata nanočestica najmanje 7,1 g/cm3 ako je metalni oksid CeO2, najmanje 8,3 g/cm3 ako je metalni oksid Tm2O3, najmanje 7,4 g/cm3 ako je metalni oksid HfO2, najmanje 7,2 g/cm3 ako je metalni oksid WO3, i najmanje 7,9 g/cm3 ako je metalni oksid PdO, i gdje je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6.5 i 7.5 u fiziološkoj tekućini.
The pharmaceutical composition according to anyone of claims 4 to 8, wherein said composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
An organophosphate or carbamate pediculicide for use in a method of treatment of a human subject to combat infestation by multicellular ectoparasites with exoskeletons, which method comprises topically applying to said subject a first and a second pediculicide, said first pediculicide being a carbamate or organophosphate pediculicide and said second pediculicide being a pyrethroid or pyrethrin pediculicide, characterized in that said second pediculicide is applied between 15 minutes and 12 hours after the application of said first pediculicide, and wherein the two pediculicides are applied as a composition for topical application in the form of a solution, a cream, a gel, a cream rinse, a dispersion, a powder, a lotion, a spray or an unguent, with at least one of the compositions being a shampoo or a cream rinse. 
Organofosfatni ili karbamatni pedikulicid, namijenjen upotrebi u postupku liječenja ljudskog subjekta radi borbe protiv infestacije višestaničnim ektoparazitima s egzoskeletom, gdje se navedeni postupak sastoji u topikalnoj primjeni na navedenom subjektu prvog i drugog pedikulicida, gdje je navedeni prvi pedikulicid karbamatni ili organofosfatni pedikulicid, a navedeni drugi pedikulicid je piretroidni ili piretrinski pedikulicid, naznačen time što se navedeni drugi pedikulicid primijenjuje između 15 minuta i 12 sati nakon primjene navedenog prvog pedikulicida, te gdje se ta dva pedikulicida primijenjuje u obliku pripravka za topikalnu primjenu u obliku otopine, kreme, gela, regeneratora, disperzije, praška, losiona, spreja ili masti, gdje je najmanje jedan od pripravaka šampon ili regenerator.
The use according to any one of the previous claims, wherein the cognitive impairment is associated with a pharmacological treatment of a disease of claim 7. 
Spojevi kako su prijavljeni u patentnom zahtjevu 1 za upotrebu prema patentnom zahtjevu 1, naznačeni time da su za liječenje kognitivnig poremećaja povezanih s farmakološkim liječenjem bolesti iz patentnog zahtjeva 1.
The pharmaceutical composition may be administered systemically, e.g. intraperitoneally, intramuscularly, or intravenously or locally such as intranasally, subcutaneously, intradermally or intrathecally. 
Farmaceutski sastav prema patentnom zahtjevu 3, gdje se farmaceutski sastav primjenjuje intraperitonealno, intramuskularno, intravenozno, intranazalno, potkožno, intradermalno ili intratekalno.
The method of claim 5 where the synucleinopathy is selected from the group consisting of Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, and the Parkinsonism-dementia complex of Guam. 
Uporaba prema zahtjevu 11 naznačena time da je sinukleinopatija odabrana iz skupine koju čine Parkinsonova bolest, nasljedna Parkinsonova bolest, bolest Lewyjevih tjelešaca, varijanta Alzheimerove bolesti s Lewyjevim tjelešcima, demencija s Lewyjevim tjelešcima, multipla sistemska atrofija, te kompleks Guam demencije s parkinsonizmom.
The pharmaceutical composition for use of any of claims 1-18, wherein the subject has, or is identified as having, one or more of: 
Molekula antitijela, ili farmaceutski sastav, za uporabu prema zahtjevu 22, pri čemu subjekt ima, ili mu je identificirano da ima, jedno ili više od:
Number of millions viable cells 
Broj međunarodne objave:
providing on said first side a surface structure having an array of formations in relief (2) such as to determine on said material a visual and tactile effect of roughness; said process being characterized in that: said step of providing said array of formations in relief envisages application on said first side of a discontinuous coating (2; 106) and/or a coating having a variable thickness that forms said array of formations in relief, said coating being constituted of a paint containing mineral fillers, substantially constituted by quartz and/or mica and/or silica, and in that it comprises a step in which said sheet material with said coating applied thereon is subjected to an operation of thermoforming, so as to undergo plastic deformation and assume the desired shape of the package or of a part of the package, or of heat-sealing, so as to close hermetically the foodstuff product inside it. 
osiguravanja na navedenoj prvoj strani površinske strukture koja ima područje formacija u obliku reljefa (2), kako bi se navedenom materijalu dalo vizualni i taktilni osjećaj grubosti; navedeni postupak naznačen time što: navedeni korak osiguravanja navedenog područja formacija u obliku reljefa se sastoji u primjeni na navedenoj prvoj strani diskontinuirane obloge (2; 106) i/ili obloge promjenjive debljine koje čini navedeno područje formacija u obliku reljefa, gdje se navedena obloga sastoji od boje koja sadrži mineralna punila, koja se uglavnom sastoje od kremena i/ili tinjca i/ili silicijevog dioksida, te što se sastoji u koraku u kojem se navedeni materijal za foliju na kojem je primijenjena navedena obloga podvrgava postupku termoformiranja, kako bi došlo do plastičnog deformiranja i postiglo se željeni oblik ambalaže ili dijela ambalaže, ili toplinskog zavarivanja, kako bi se hermetično zatvorilo sadržani prehrambeni proizvod.
The composition of claim 1, wherein the carbohydrate is present in an amount sufficient that upon storage, in a gas tight container, at a temperature of 2-8° C., for a period of 6 months, the composition will retain at least 85% of the stability the composition had prior to storage. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da poslije čuvanja u kontejneru nepropusnom za plin, na temperaturi od 2-8%C, u razdoblju od 6 mjeseci, kompozicija zadrži najmanje 85% stabilnosti koju je kompozicija imala prije čuvanja.
A dental filling material consisting of 9.980 g bis-GMA and 9.975 g TEGDMA is prepared. 
Pripravljen je dentalni materijal za punjenje koji se sastoji od 9.980 g bis-GMA i 9.975 g TEGDMA.
Use of trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrole (Z)-2-butenedioate in the orthorhombic crystal form in the preparation of a pharmaceutical formulation for the treatment of mental disorders in a mammal, including a human. 
Uporaba trans-5-kloro-2,3,3a, 12b-tetrahidro-2-metil-1H-dibenz [2,3:6,7] oksepino [4,5-c] pirol (Z)-2-butendioata u ortorombskom kristalnom obliku za dobivanje farmaceutskih pripravaka, naznačenih time, da se rabe za liječenje mentalnih poremećaja u sisavaca, uključujući čovjeka.
The present invention provides methods of recycling solid supports for cultivation of anchorage-dependent cells in situ. 
Ovaj izum osigurava postupke za recikliranje krutih potpora za in situ uzgoj stanica koje potrebuju pričvršćivanje.
drying the web (154), wherein the papermaking furnish is selected and the steps of belt-creping and drying are controlled such that the dried web has: 
(d) sušenjem strukture (154), pri čemu je oprema izrade papira odabrana, a koraci krepiranja remenom i sušenja su kontrolirani tako da osušena struktura ima:
A beverage preparation machine (1) according to claim 1, wherein said valve is a spring-mounted poppet valve, disposed at the dispensing opening of the tank (2), such that its valve stem rests onto the machine surface, and its spring is in contact at one end with the valve stem, and on the other end with the reservoir. 
Stroj za pripravu napitaka (1) u skladu s patentnim zahtjevom 1, naznačen time što je navedeni ventil gljivasti ventil s oprugom, koji se nalazi na otvoru za ispust spremnika (2), tako da osovina ventila počiva na površini stroja, a njegova opruga je u kontaktu, na svom jednom kraju, s osovinom ventila, a na svom drugom kraju sa spremnikom.
Compositions as claimed in claim 1, wherein the colostrum fraction is obtainable from bovine colostrum milked between the 5th and 6th hours after calving and wherein said colostrum fraction is treated with a process which comprises: 
3. - Pripravci kako su prijavljeni u patentnom zahtjevu 1 ili 2, naznačeno time da se frakcija kolostruma može dobiti od kravljeg kolostruma pomuzenog između petog i šestog sata nakon teljenja na kojega je djelovano postupkom koji se sastoji od:
dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 61.66 mg; 
dapagliflozin propilen glikol hidrat, pri čemu je dapagliflozin propilen glikol hidrat prisutan u količini od 61,66 mg;
0.01-0.6 % by weight of micronised fluticasone propionate or a pharmaceutically acceptable salt or derivative thereof; 
0,01-0,6%, težinski, mikroniziranog flutikazon-propionata, ili njegove farmaceutski prihvatljive soli ili derivata;
Method according to claim 2, wherein cleaning and degreasing is made by spraying the strip with an aqueous solution of 5 to 50 g/l, preferably 15 to 25 g/I, of an initial solution comprising 0.10 to 1.0 wt.-% bisoctyl dimethyl ammonium chloride, 5 to 10 wt.-% potassium hydroxide, 5 to 10 wt.-% phosphate (P) and < 5 wt.-% cationic tenside. 
Postupak prema zahtjevu 2, naznačen time, da se čišćenje 1 odmašćivanje vrši putem sprejanja trake s vodenom otopinom od 5 do 50 g/l, poželjno od 15 do 25 g/l početne otopine koja sadrži od 0,10 do 1,0 masenog % dimetildioktil-amonij-klorida, od 5 do 10 masenih % kalij-hidroksida, od 5 do 10 masenih % fosfata (P) i < 5 masenih % kationskog tenzida.
mixing of vulcanized crumb rubber, SBS and lubricant inside an extruder, wherein the weight percentage of lubricant is between 1% and 50% with respect to the weight of mixture, and vulcanized crumb rubber is in weight percentage 70-100% with respect to SBS weight; 
- < miješanje vulkanizirane gume u mrvicama, aditiva SBS (stiren-butadien-stiren) i maziva unutar ekstrudera, pri čemu je težinski postotak maziva između 1% i 50% u odnosu na težinu smjese, a težinski postotak vulkanizirane gume mrvicama je jednak težinskom postotku SBS-a;
A compound selected from the group consisting of: A method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject a compound according to claim 1 . 
Spoj ili sol prema patentnom zahtjevu 5, naznačen time što je za upotrebu u postupku inhibicije voltažno-ovisnog natrijevog kanala kod subjekta.
The method of claim 1, wherein only the compound of Formula (I) is isolated. 
Metoda iz bilo kojeg od prethodnih zahtjeva, naznačena time, što se izolira samo spoj Formule (I).
inhibition of VEGF secretion of cells expressing ErbB3; 
(V) inhibicija izlučivanja VEGF od strane stanica koje eksprimiraju ErbB3;
a centrally located core (20, 38) provided with an upper side (38a) and a lower side (38b), 
središnje smještenu jezgru (20, 38), koja ima gornju stranu (384) i donju stranu (38b), -
The combined aqueous extract was washed with ether (2 X 200 ml. 
Spojeni vodeni ekstrakt se ispere sa eterom (2x200 ml.
aryl-C1-2 alkyl. A compound according to claim 1 wherein R1 represents C1-8 alkyl or C3-8 cycloalkyl-C0-6 alkyl, wherein any alkyl group may be optionally substituted with one or more halogen groups and the C3-8 cycloalkyl group may be optionally substituted with one or more substituents independently selected from C1-4 alkyl, halogen and aryl; preferably R1 represents C1-8 alkyl or C3-8 cycloalkyl-C0-6 alkyl; more preferably R1 represents C4-6 alkyl or C3-8 cycloalkyl-C0-1 alkyl; and still more preferably R1 represents isobutyl, 2,2-dimethylpropyl, cyclobutyl, cyclopentyl cyclohexyl, cyclohexylmethyl or cyclopropylmethyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da R; predstavlja C,_g alkil ili C3_g cikloalkil-C4.4 alkil, pri čemu bilo koja alkilna skupina po izboru može biti supstituirana s jednom ili više skupina halogena i Cas cikloalkilna skupina po izboru može biti supstituirana s jednim ili više supstituenata neovisno odabranih od C,4 alkila, halogena 1 arila; poželjno je da R, predstavlja C,.g alkil 1li C3g cikloalkil-C9.5 alkil; još poželjnije da R, predstavlja Cas alkil ili Cs.g cikloalkil-Co., alkil; a još je više poželjno da R, predstavlja izobutil, 2,2-dimetilpropil, ciklobutil, ciklopentil cikloheksil, cikloheksilmetil ili ciklopropilmetil.
A compound selected from the group consisting of: 
Dimerski spoj prema zahtjevu 8, izabran iz grupe koja obuhvaća:
The vaccine composition according Claim 1 wherein said composition is an homogenous mix of the conjugated hrEGF-rP64K being free of others molecular species like hrEGF polymers or free hrEGF. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je spomenuti sastav homogena mješavina konjugirane hrEGF- IP6AK, koja je oslobođena od ostalih vrsta molekula kao što su hrEGF polimeri ili slobodna hrEGF.
a buffer comprising sodium acetate tri-hydrate and potassium acetate. 
(d) pufer koji sadrži natrijev acetat trihidrat i kalijev acetat.
The process according to claim 19, wherein the botulinum toxin is a botulinum toxin belonging to Clostridium botulinum of types A, B, C, D, E, F, and G, or is a mixture of two or more of these types. 
Postupak prema Zahtjevu 19, naznačen time da je toksin botulinum toksin botulinum iz bakterije Clostridium botulinum tipa A, B, C, D, E, F, i G, ili smjesa dvaju ili više navedenih tipova, poželjno toksin botulinum tipa A.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of transthyretin (TTR), wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region complementary to a part of a mRNA encoding transthyretin (TTR), wherein said region of complementarity is 19 nucleotides in length, the antisense strand comprises SEQ ID NO:170, and each strand of the dsRNA is 19, 20, 21, 22, 23, or 24 nucleotides in length; or 
Dvolančana ribonukleinska kiselina (AsRNA) za inhibiranje ekspresije transtiretina (TTR), naznačena time da (a) navedena dsRNA sadrži sensni lanac i antisensni lanac, te antisensni lanac sadrži regiju komplementarnu s dijelom mRNA koja kodira transtiretin (TTR), pri čemu je navedena regija komplementarnosti duljine 19 nukleotida, te antisensni lanac sadrži SEQ ID NO:170, 1 svaki lanac dsRNA je duljine 19, 20, 21, 22, 23, ili 24 nukleotida; ili
concentrating the aqueous suspension of ground mineral material of step c) by flash cooling. 
koncentriranje vodene suspenzije mljevenog mineralnog materijala iz koraka c) brzim hlađenjem, naznačen time da
In still another embodiment, the amino acid is glycine at a concentration of about 15 mM. 
Formulacija prema zahtjevu 7, naznačena time da je amino kiselina glicin pri koncentraciji od oko 15 mM u otopini.
reacting a compound of Formula (V), wherein R is methyl, p-tolyl, naphtyl; 
(V) pri čemu R je metil, p-tolil, naftil; ili reakciju spoja prema formuli (VI), OH
An anti-CD20 antibody formulation comprising 20 - 300 mg/ml of atumumab, 10 to 100 mM sodium acetate, 25 to 100 mM sodium chloride, 0.5 to 5% arginine free base, 0.02 to 0.2 mM EDTA, 0.01 to 0.2% polysorbate 80 and adjusted to pH 5.0 to 7.0, for use in the treatment of an immune disease and/or autoimmune disease. 
Formulacija protutijela anu-CID20, naznačena time, da obuhvaća od 20 do 300 mg/mL, ofatumumaba, od 10 do 100 miM natrijevog acetata, od 25 do 100 mM natrijevog klorida, od 0,5 do 5% slobodne baze arginina, od 0,02 do 0.2 mM EDTA, od 0,01 do 0,2% polisorbata 80, i podešava se na pH-vrijednost od 5,8 do 7,0, pri čem se ona upotrebljava u liječenju imunološke bolesti i/ili autoimune bolesti.
R4y is hydrogen, C1-4 alkyl, C1-4 fluoroalkyl, C6-10 ar(C1-4)alkyl, the aryl portion of which may be optionally substituted, or an optionally substituted 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring; or 
y je vodik, C1-4 alkil, C1-4 fluoralkil, C6-10 ar(C1-4)alkil, čiji arilni dio može biti izborno supstituiran, ili izborno supstituiran 5- ili 6-eročlani aril, heteroaril ili heterociklil prsten; ili